Excimer laser refractive surgery : corneal wound ... - Helda - Helsinki.fi
Excimer laser refractive surgery : corneal wound ... - Helda - Helsinki.fi
Excimer laser refractive surgery : corneal wound ... - Helda - Helsinki.fi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
of 10 kHz requiring relatively a long time of flap creation, but, nowadays the current FS<br />
<strong>laser</strong> <strong>fi</strong>res at a rate of 60 kHz resulting in much lower times for flap creation. Fifth<br />
generation FS have even reached a <strong>fi</strong>ring rate of 150 kHz further reducing the flap creation<br />
time and decreasing the energy needed. The major advantages of FS <strong>laser</strong> systems over<br />
microkeratomes are increase in flap homogeneity and a higher rate of reproducibility. A<br />
capacity to create flaps of different diameters and thicknesses, even under 90 µm have<br />
decrease the flaps related complications (Durrie and Kezirian 2005, Kezirian and<br />
Stonecipher 2004) and increases postoperative flap adhesion (Knorz and Vossmerbaeumer<br />
2008). Complications with FS are rare, being most commonly transient light-sensitive<br />
syndrome (TLSS) and diffuse lamellar keratitis (DLK). The mechanism of TLSS is still<br />
unknown, yet it seems to be secondary to an inflammatory response to the gas bubbles or<br />
keratocytes’ response to <strong>laser</strong> ablation.<br />
Postoperative visual outcomes between microkeratomes and FS have not shown any<br />
differences (Javaloy et al. 2007, Montes-Mico et al. 2007a), although the contrast<br />
sensitivity seems to be better after FS (Montes-Mico et al. 2007b), yet the complication<br />
rate between both groups is similar (Moshirfar et al. 2010).<br />
2.4 CORNEAL WOUND HEALING<br />
Wound healing is essential to maintain the transparency and optical properties of the<br />
cornea. Physiology diversity in response to injury is a major factor in outcome results after<br />
<strong>refractive</strong> <strong>surgery</strong>. PRK and LASIK differ in the intensity of <strong>corneal</strong> <strong>wound</strong> healing. This<br />
difference seems to be secondary to the preservation of epithelium and Bowman’s layer<br />
after LASIK (Ambrosio and Wilson 2003, Helena et al. 1998, Mohan et al. 2003, Tervo<br />
and Moilanen 2003, Wilson et al. 2007) and the amount of depth of photoablation in both<br />
procedures (Moller-Pedersen et al. 1998, Moller-Pedersen et al. 2000).<br />
The mechanisms behind <strong>corneal</strong> <strong>wound</strong> healing response form a complex cascade of<br />
events involving epithelial cells, keratocytes, <strong>corneal</strong> nerves, lacrimal glands, tear <strong>fi</strong>lm,<br />
and cells of the immune system. Cytokines and growth factors are the soluble factors that<br />
mediate the signals and interaction between different cells and components to restore<br />
<strong>corneal</strong> functionality. In the following I will describe <strong>corneal</strong> <strong>wound</strong> response in different<br />
layers of the cornea in more detail.<br />
Epithelial <strong>corneal</strong> debridment from its basement membrane generates apoptosis in<br />
keratocytes followed by simple epithelial replacement by mitosis without any <strong>fi</strong>brosis. If<br />
epithelial injury compromises the basement membrane it stimulates a <strong>fi</strong>brotic response<br />
(Zieske et al. 2001). In the case of PRK the <strong>fi</strong>brotic response involves a higher area<br />
compared to LASIK in which the <strong>fi</strong>brosis response is limited to the edges of the flap<br />
created by the microkeratome.<br />
Immediately after an epithelial injury an anterior stromal keratocyte apoptosis can be<br />
observed (Dupps and Wilson 2006, Wilson et al. 1996). This continues for at least one<br />
week. This response is mediated by the release of cytokines such as Interleukin (IL)-<br />
1(Wilson et al. 1996), tumour necrosis factor (TNF)-α (Wilson et al. 2001), epidermal<br />
growth factor (EGF) and platelet derived growth factor (PDGF) (Tuominen et al. 2001).<br />
22